Form 4: OnKure Therapeutics Director Acquires Shares Through Restricted Stock Units

Director Edward T. Mathers acquired 2,580 shares of OnKure Therapeutics Class A Common Stock through fully vested restricted stock units (RSUs) in lieu of a quarterly cash retainer.

Summary

• On March 31, 2025, Edward T. Mathers, a director of OnKure Therapeutics, Inc., acquired 2,580 shares of Class A Common Stock.
• The acquisition was made through fully vested restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Class A Common Stock.
• The RSUs were granted in lieu of a quarterly cash retainer, as per the Issuer's Outside Director Compensation Policy.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The acquisition of shares by a director could be interpreted as slightly positive, but the filing itself is primarily informational.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's investment in the company.

Key Dates

Keywords

OnKure Therapeutics, Director, Edward T. Mathers, Class A Common Stock, Restricted Stock Units, RSUs, Acquisition, Insider Trading, Form 4